According to the Scottish government, a new manufacturing facility built by GSK in Montrose to produce APIs for its Ellipta dry powder inhalers officially opened on October 22, 2018, with Scottish First Minister Nicola Sturgeon in attendance.
Sturgeon commented, “This new facility is testament to GSK’s commitment to Montrose and reinforces the region’s position alongside Singapore as the two sites producing APIs for all of GSK’s Ellipta respiratory inhaler portfolio.”
GSK CEO Emma Walmsley said,“The state-of-the-art facility we are opening today represents a £54 million investment in GSK Montrose and is testament to the highly-skilled workforce at the site. It also highlights the important part Montrose will play in our future growth, based around our latest medicines for respiratory, HIV and vaccines.
FM @nicolasturgeon opened @GSK's new £54 million building in Montrose where active pharmaceutical ingredients for respiratory inhalers will be produced https://t.co/wSMygnExcv pic.twitter.com/ihGQmoR8hs
— First Minister (@ScotGovFM) October 22, 2018
Read the Scottish government press release.
